OncoMatch/Clinical Trials/NCT07449754
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Is NCT07449754 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Belvarafenib and Cobimetinib for advanced or metastatic melanoma.
Treatment: Belvarafenib · Cobimetinib — This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations. The study plans to assess ORR, DCR, DOR, TTP, PFS, OS and safety of the participating subjects. Treatment cycles for all subjects will be 28 days in duration and Belvarafenib and Cobimetinib will be administered orally in combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Required: NRAS mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: raf inhibitor
Cannot have received: mek inhibitor
Cannot have received: erk inhibitor
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify